About Us

Driven by innovation and purposeful science

Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology.

SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer.

At SDP Oncology, we are relentlessly exploring novel and unique approaches to address unmet needs in oncology research and development. Through scientific persistence and a commitment to discovery, we are focused on advancing a diverse and purposeful pipeline.

Learn more about our leadership.

Our Mission

We are dedicated to the promise of purposeful science to advance cancer treatment options aimed at positively impacting outcomes for patients with cancer.

Learn about our science and see our diverse pipeline.

Our Commitment

SDP Oncology is committed to developing a diverse and purposeful pipeline of novel targets. Augmenting this effort, SDP Oncology’s Global Oncology External Innovation Hub was established to help spark meaningful research in drug discovery for oncology.

We also have a responsibility to serve our local communities. From Utah to Massachusetts to Japan, we are committed to supporting and understanding the needs of patients and families living with cancer.

Learn more about our Global Oncology External Innovation Hub and other community efforts.

Join Us

Bring your passion for making a meaningful difference, and join our global team to transform new discoveries into meaningful options for patients with cancer.